FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Conditions
Gastric Cancer | Gastroesophageal Cancer
What is the purpose of this trial?
This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in patients treated with FOLFOX in combination with bevacizumab.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Genentech
Yale University - Dates:
- May 2008
- Last Updated:
- February 25, 2013
- Study HIC#:
- 0710003118
Clinicaltrials.gov ID: NCT00673673
